266 research outputs found
The Prostacyclin Analogue Iloprost as an Early Predictor of Successful Revascularization in Diabetic Patients Affected by Critical Limb Ischemia and Foot Ulcers
Abstract Purpose The aim of this study is to evaluate the role of Iloprost as an early predictor of successful revascularization in patients affected by ischemic diabetic foot ulcers (DFUs). Methods Consecutive patients with ischemic DFUs with persistent low TcPO2 ( All patients underwent Iloprost infusion and TcPO2 has been recorded at days 3, 14 and 30. According to the TcPO2 reported at day 3, patients were divided into two groups: group A (patients with TcPO2 ≥30mmHg) and group B (patients with TcPO2  Results Twenty-five patients have been included, 12/25 (48%) in Group A and 13/25 (52%) in Group B. There were no significant differences at the baseline and one day after PTA between the two groups while TcPO2 values recorded in Group A at days 3, 14 and 30 after Iloprost infusion were significant higher in comparison to the Group B (χ = 0.005). The rate of re-PTA were respectively 33,3% (Group A) and 53,8% (Group B) (p = 0.03). Conclusions Iloprost may be an early predictor of successful revascularization in patients affected by critical limb ischemia (CLI) and DFUs
Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
BACKGROUND:
A beneficial effect on cardiovascular risk may be obtained by improving lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by reducing proprotein convertase subtilisin kexin type 9 (PCSK9), independently of lipoprotein concentrations.
AIM:
We aimed to evaluate the effect of an innovative nutraceutical (NUT) combination containing red yeast rice (monacolin K 3.3 mg), berberine 531.25 mg and leaf extract of Morus alba 200 mg (LopiGLIK®), on HDL-CEC, serum CLC and on circulating PCSK9 levels.
MATERIALS AND METHODS:
Twenty three dyslipidemic subjects were treated for 4 weeks with the above NUT combination. HDL-CEC was measured using specific cell-based radioisotopic assays; serum CLC and PCSK9 concentrations were measured fluorimetrically and by enzyme-linked immunosorbent assay, respectively.
RESULTS:
The NUT combination significantly reduced plasma level of the total cholesterol and low-density lipoprotein cholesterol (-9.8% and -12.6%, respectively). Despite no changes in HDL-cholesterol, the NUT combination improved total HDL-CEC in 83% of the patients, by an average of 16%, as a consequence of the increase mainly of the ATP-binding cassette A1-mediated CEC (+28.5%). The NUT combination significantly reduced serum CLC (-11.4%) while it did not change PCSK9 plasma levels (312.9±69.4 ng/mL vs 334.8±103.5 mg/L, before and after treatment, respectively).
CONCLUSION:
The present NUT combination improves the serum lipoprotein functional profile providing complementary beneficial effects, without any detrimental increase of PCSK9 plasma levels
Insufficient control of blood pressure and incident diabetes
OBJECTIVE:
Incidence of type 2 diabetes might be associated with preexisting hypertension. There is no information on whether incident diabetes is predicted by blood pressure control. We evaluated the hazard of diabetes in relation to blood pressure control in treated hypertensive patients.
RESEARCH DESIGN AND METHODS:
Nondiabetic, otherwise healthy, hypertensive patients (N = 1,754, mean +/- SD age 52 +/- 11 years, 43% women) participated in a network over 3.4 +/- 1 years of follow-up. Blood pressure was considered uncontrolled if systolic was >or=140 mmHg and/or diastolic was >or=90 mmHg at the last outpatient visit. Diabetes was defined according to American Diabetes Association guidelines.
RESULTS:
Uncontrolled blood pressure despite antihypertensive treatment was found in 712 patients (41%). At baseline, patients with uncontrolledblood pressure were slightly younger than patients with controlled blood pressure (51 +/- 11 vs. 53 +/- 12 years, P < 0.001), with no differences in sex distribution, BMI, duration of hypertension, baseline blood pressure, fasting glucose, serum creatinine and potassium, lipid profile, or prevalence of metabolic syndrome. During follow-up, 109 subjects developed diabetes. Incidence of diabetes was significantly higher in patients with uncontrolled (8%) than in those with controlled blood pressure (4%, odds ratio 2.08, P < 0.0001). In Cox regression analysis controlling for baseline systolic blood pressure and BMI, family history of diabetes, and physical activity, uncontrolled blood pressure doubled the risk of incident diabetes (hazard ratio [HR] 2.10, P < 0.001), independently of significant effects of age (HR 1.02 per year, P = 0.03) and baseline fasting glucose (HR 1.10 per mg/dl, P < 0.001).
CONCLUSIONS:
In a large sample of treated nondiabetic hypertensive subjects, uncontrolled blood pressure is associated with twofold increased risk of incident diabetes independently of age, BMI, baseline blood pressure, or fasting glucose
Insufficient control of blood pressure and incident diabetes
OBJECTIVE:
Incidence of type 2 diabetes might be associated with preexisting hypertension. There is no information on whether incident diabetes is predicted by blood pressure control. We evaluated the hazard of diabetes in relation to blood pressure control in treated hypertensive patients.
RESEARCH DESIGN AND METHODS:
Nondiabetic, otherwise healthy, hypertensive patients (N = 1,754, mean +/- SD age 52 +/- 11 years, 43% women) participated in a network over 3.4 +/- 1 years of follow-up. Blood pressure was considered uncontrolled if systolic was >or=140 mmHg and/or diastolic was >or=90 mmHg at the last outpatient visit. Diabetes was defined according to American Diabetes Association guidelines.
RESULTS:
Uncontrolled blood pressure despite antihypertensive treatment was found in 712 patients (41%). At baseline, patients with uncontrolledblood pressure were slightly younger than patients with controlled blood pressure (51 +/- 11 vs. 53 +/- 12 years, P < 0.001), with no differences in sex distribution, BMI, duration of hypertension, baseline blood pressure, fasting glucose, serum creatinine and potassium, lipid profile, or prevalence of metabolic syndrome. During follow-up, 109 subjects developed diabetes. Incidence of diabetes was significantly higher in patients with uncontrolled (8%) than in those with controlled blood pressure (4%, odds ratio 2.08, P < 0.0001). In Cox regression analysis controlling for baseline systolic blood pressure and BMI, family history of diabetes, and physical activity, uncontrolled blood pressure doubled the risk of incident diabetes (hazard ratio [HR] 2.10, P < 0.001), independently of significant effects of age (HR 1.02 per year, P = 0.03) and baseline fasting glucose (HR 1.10 per mg/dl, P < 0.001).
CONCLUSIONS:
In a large sample of treated nondiabetic hypertensive subjects, uncontrolled blood pressure is associated with twofold increased risk of incident diabetes independently of age, BMI, baseline blood pressure, or fasting glucose
Multi-analytical investigation on felt-tip pen inks: Formulation and preliminary photo-degradation study
We present a multi-analytical study on the formulation of commercial felt-tip pens, introduced in the second half of the 20th century and commonly used by modern and contemporary artists. These media of both drawing and writing have not yet been fully investigated, but the degradation processes they might undergo, such as fading, are well-known and rather apparent.Twelve water-based felt-tip pens were investigated by the joint use of complementary analytical techniques, such as Thin Layer Chromatography, Nuclear Magnetic Resonance, Fourier transformed infrared spectroscopy, X-ray fluorescence spectrometry and Pyrolysis-Gas Chromatography/Mass Spectrometry.The obtained results provided crucial, preliminary data for the identification of dyes, solvents and additives present in the inks' formulations. Numerous synthetic food coloring agents and pigments were identified, such as Acid Yellow 23, Acid Red 18, Acid Blue 9, and Pigment Blue 15. In addition, glycols, fatty acids, 2-phenoxyethanol, colophony, benzotriazole derivatives and other solvents and additives were detected in the manufactured inks.Furthermore, the effects of photo-degradation on one emblematic ink sample were studied, highlighting in particular visual and aesthetical changes due to discoloration.This study demonstrates a methodology based upon the use of an integrated analytical approach for the characterization of commercial ink-based artistic media and their viable degradation patterns, which aims to develop suitable conservation treatments to assess modern and contemporary drawings and writings. (C) 2015 Elsevier B.V. All rights reserved
A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk
Context: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.
Objective: To evaluate the cost and effectiveness of LopiGLIK® (LOPI) in lowering LDL-C and CVD risk.
Design: Single blind multicenter randomized controlled trial; patients were divided into two groups, subjected to centralized randomization.
Setting: Four Italian regions.
Participants: Thirty-one physicians enrolled 573 adult patients with mild hypercholesterolemia between January 2016 and January 2018.
Intervention: Patients were treated for 16 weeks either with LOPI (intervention) or Armolipid Plus® (AP; control).
Outcome measures: Primary outcome: percentage of patients who achieved LDL-C <130 mg/dL. Secondary outcomes: reduction of HbA1c, survival analysis and HR linked to 38.67 mg/dL reduction of LDL-C and 1% reduction of HbA1c. Costs were assessed per unit and cure.
Results: Three hundred and seventy patients treated with LOPI and 203 treated with AP were randomized and completed the study. At baseline 8.9% (n=18) patients treated with AP and 9.5% (n=35) treated with LOPI had LDL-C levels <130 mg/dL (P=0.815). At the 16-week follow-up, 41.4% (n=84) of patients treated with AP and 67.6% (n=250) with LOPI achieved LDL-C levels <130 mg/dL (P<0.001). LOPI patients were three times more likely to achieve LDL-C levels <130 mg/dL; adjusted OR 2.97 (95% CI; 2.08–4.24; P<0.001), number needed to treat was four (95% CI; 5.60–2.90; P<0.001). Survival analysis demonstrated the superiority of LOPI vs AP relative to 38.67 mg/dL LDL-C reduction (P<0.002); HR was 0.761 (95% CI; 0.62–0.94; P<0.001). Both products reduced the HbA1c without a significant difference between them (P=0.156). Survival analysis and HR (0.91; 95% CI; 0.70–1.18) estimated for 1% HbA1c reduction, showed differences between LOPI and AP, which were not significant (P=0.411; P=0.464). The cost of LOPI was €2.11 (unit), €211 (cure), and AP €3.77 and €377, respectively.
Conclusion: LOPI appeared more effective and less expensive than AP in lowering LDL-C and CVD risk.
Trial registration: NCT02898805, September 8, 2016.
Keywords: hypercholesterolemia, nutraceuticals, effectiveness, cardiovascular risk reductio
The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy.
The study investigated the diagnostic performance for diabetic cardiovascular autonomic
neuropathy (CAN) and diabetic polyneuropathy (DPN) of the combined use of
composite autonomic symptom score (COMPASS) 31, validated questionnaire for
autonomic symptoms of CAN, and electrochemical skin conductance (ESC), proposed
for detecting DPN and CAN. One-hundred and two participants with diabetes (age
57 ± 14 years, duration 17 ± 13 years) completed the COMPASS 31 before assessing
cardiovascular reflex tests (CARTs), neuropathic symptoms, signs, vibratory perception
threshold (VPT), thermal thresholds (TT), and ESC using Sudoscan. Two patterns
were evaluated: (a) the combined abnormalities in both tests (COMPASS 31+ESC),
and (b) the abnormality in COMPASS 31 and/or ESC (COMPASS 31 and/or ESC). CAN
(≥1 abnormal CART) and confirmed CAN (≥2 abnormal CARTs) were present in
28.1% and 12.5%, DPN (two abnormalities among symptoms, signs, VPT, and TT) in
52%, abnormal COMPASS 31 (total weighted score >16.44) in 48% and abnormal
ESC (hands ESC <50 μS and/or feet ESC <70 μS) in 47.4%. Both the patterns—COMPASS
31+ESC and COMPASS 31 and/or ESC—were associated with CAN and DPN
(P < .01). COMPASS 31 and ESC reached a sensitivity of 75% and 83% for confirmed
CAN, and a specificity of 65% and 67% for DPN. When combining the tests, the sensitivity
for CAN rose by up to 100% for CAN and the specificity up to 89% for DPN.
The combination of the tests can allow a stepwise screening strategy for CAN, by
suggesting CAN absence with combined normality, and prompting to CARTs with combined abnormality
Insulin autoimmune syndrome in an Argentine woman taking α-lipoic acid: A case report and review of the literature.
Insulin autoimmune syndrome is an unusual cause of spontaneous hypoglycaemia in non-Asian populations. In the majority
of cases, this syndrome appears a few weeks after the administration of drugs containing a sulfhydryl group. A strong
association between this syndrome and HLA-DR4 has been shown. Only seven cases have been described in non-Asian
patients. We report the first case of insulin autoimmune syndrome in an Argentine woman taking alfa-lipoic acid. She
developed hypoglycaemic symptoms approximately 1 month after starting therapy. Blood sampling collected during an episode
of symptomatic hypoglycaemia showed low blood glucose level (2.39 mmol/L), high level of serum insulin (1971.55 pmol/L),
inappropriately high level of C-peptide (2.36 nmol/L) and high levels of insulin antibodies (274.78 IU/mL). HLA-DNA typing
identified DRB1*04:03. Due to the widespread use of alfa-lipoic acid for its antioxidant properties, clinicians should be aware
that it may trigger an autoimmune hypoglycaemia in people with a genetic predisposition
Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk
- …